INS and type 1 diabetes mellitus: Dovc et al., in an article from 2024, summarize relevant research describing alternative implementations of CGM systems, among others: in stage 2 of T1D as indicators of progression to stage 3; in patients with type 2 diabetes (T2D) in non-insulin therapy; and people without diabetes [9].